Clinical practice guidelines of the Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis for the management of microscopic polyangiitis and granulomatosis with polyangiitis : The 2023 update - secondary publication
© Japan College of Rheumatology 2023. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com..
OBJECTIVE: To revise the 2017 clinical practice guidelines (CPG) for the management of microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA) to reflect advancements in the field.
METHODS: Similar to the 2017 CPG, the Grading of Recommendations, Assessment, Development, and Evaluation system was adopted for this revision. The intended users of this CPG include patients diagnosed with MPA or GPA in Japan and their families and healthcare professionals, including specialists and non-specialists. Based on a scoping review, four clinical questions (CQs) of the 2017 guidelines were modified, and six new CQs were added.
RESULTS: We suggest a combination of glucocorticoid and cyclophosphamide or rituximab for remission induction therapy. In cases where cyclophosphamide or rituximab is used, we suggest the use of avacopan over high-dose glucocorticoid. Furthermore, we suggest against the use of plasma exchange in addition to the standard treatment in severe cases of MPA/GPA. Finally, we suggest the use of glucocorticoid and rituximab over glucocorticoid and azathioprine for remission maintenance therapy.
CONCLUSIONS: The recommendations have been updated based on patient preference, certainty of evidence, benefit and risk balance, and cost.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:34 |
|---|---|
| Enthalten in: |
Modern rheumatology - 34(2024), 3 vom: 28. März, Seite 559-567 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sada, Ken-Ei [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 29.03.2024 Date Revised 11.04.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/mr/road081 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM360981585 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM360981585 | ||
| 003 | DE-627 | ||
| 005 | 20240411232105.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/mr/road081 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1372.xml |
| 035 | |a (DE-627)NLM360981585 | ||
| 035 | |a (NLM)37599461 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sada, Ken-Ei |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical practice guidelines of the Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis for the management of microscopic polyangiitis and granulomatosis with polyangiitis |b The 2023 update - secondary publication |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.03.2024 | ||
| 500 | |a Date Revised 11.04.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © Japan College of Rheumatology 2023. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com. | ||
| 520 | |a OBJECTIVE: To revise the 2017 clinical practice guidelines (CPG) for the management of microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA) to reflect advancements in the field | ||
| 520 | |a METHODS: Similar to the 2017 CPG, the Grading of Recommendations, Assessment, Development, and Evaluation system was adopted for this revision. The intended users of this CPG include patients diagnosed with MPA or GPA in Japan and their families and healthcare professionals, including specialists and non-specialists. Based on a scoping review, four clinical questions (CQs) of the 2017 guidelines were modified, and six new CQs were added | ||
| 520 | |a RESULTS: We suggest a combination of glucocorticoid and cyclophosphamide or rituximab for remission induction therapy. In cases where cyclophosphamide or rituximab is used, we suggest the use of avacopan over high-dose glucocorticoid. Furthermore, we suggest against the use of plasma exchange in addition to the standard treatment in severe cases of MPA/GPA. Finally, we suggest the use of glucocorticoid and rituximab over glucocorticoid and azathioprine for remission maintenance therapy | ||
| 520 | |a CONCLUSIONS: The recommendations have been updated based on patient preference, certainty of evidence, benefit and risk balance, and cost | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a ANCA-associated vasculitis | |
| 650 | 4 | |a clinical practice guideline | |
| 650 | 4 | |a grading of recommendations, assessment, development, and evaluation system | |
| 650 | 4 | |a granulomatosis with polyangiitis | |
| 650 | 4 | |a microscopic polyangiitis | |
| 650 | 7 | |a Antibodies, Antineutrophil Cytoplasmic |2 NLM | |
| 650 | 7 | |a Cyclophosphamide |2 NLM | |
| 650 | 7 | |a 8N3DW7272P |2 NLM | |
| 650 | 7 | |a Glucocorticoids |2 NLM | |
| 650 | 7 | |a Immunosuppressive Agents |2 NLM | |
| 650 | 7 | |a Rituximab |2 NLM | |
| 650 | 7 | |a 4F4X42SYQ6 |2 NLM | |
| 700 | 1 | |a Nagasaka, Kenji |e verfasserin |4 aut | |
| 700 | 1 | |a Kaname, Shinya |e verfasserin |4 aut | |
| 700 | 1 | |a Nango, Eishu |e verfasserin |4 aut | |
| 700 | 1 | |a Kishibe, Kan |e verfasserin |4 aut | |
| 700 | 1 | |a Dobashi, Hiroaki |e verfasserin |4 aut | |
| 700 | 1 | |a Hiromura, Keiju |e verfasserin |4 aut | |
| 700 | 1 | |a Kawakami, Tamihiro |e verfasserin |4 aut | |
| 700 | 1 | |a Bando, Masashi |e verfasserin |4 aut | |
| 700 | 1 | |a Wada, Takashi |e verfasserin |4 aut | |
| 700 | 1 | |a Amano, Koichi |e verfasserin |4 aut | |
| 700 | 1 | |a Murakawa, Yohko |e verfasserin |4 aut | |
| 700 | 1 | |a Harigai, Masayoshi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Modern rheumatology |d 2000 |g 34(2024), 3 vom: 28. März, Seite 559-567 |w (DE-627)NLM162086628 |x 1439-7609 |7 nnns |
| 773 | 1 | 8 | |g volume:34 |g year:2024 |g number:3 |g day:28 |g month:03 |g pages:559-567 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/mr/road081 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 34 |j 2024 |e 3 |b 28 |c 03 |h 559-567 | ||